Abbvie (ABBV) PT Raised to $128 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts ABBV Hot Sheet
Price: $284.80 -1.48%
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
28 Buy, 10 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Mizuho Securities analyst Vamil Divan raised the price target on Abbvie (NYSE: ABBV) to $128.00 (from $126.00) while maintaining a Buy rating.
You May Also Be Interested In
- Morgan Stanley Downgrades NEXTDC Ltd. (NXT:AU) to Equalweight
- Inchcape Plc (INCH:LN) PT Lowered to GBP7 at UBS
- AbbVie Named Official Pharmaceutical Partner of the McLaren Mastercard Formula 1 Team, Launches AbbVie Race to Innovate to Support Immunology Community
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
